Citation

Narasimhan M, Pae CU, Masand N, Masand P. Int. J. Psychiatry Clin. Prac. 2007; 11(2): 102-111.

Copyright

(Copyright © 2007, Informa - Taylor and Francis Group)

DOI

10.1080/13651500600973568

PMID

unavailable

Abstract

Partial compliance with antipsychotic medications is a common and complex phenomenon that is underestimated by physicians. The consequences of partial compliance include an increased risk of relapse, rehospitalization and suicide attempts. Stigma, negative attitudes towards medications, cognitive impairment and diminished insight negatively impact treatment adherence. Oral atypical antipsychotics may improve both insight and cognitive function, but compliance with these agents is not assured. Depot conventional antipsychotics ensure medication delivery but are associated with side-effects such as EPS and dysphoria that decrease compliance. Long-acting atypicals provide significant symptom improvement, foster adherence and may help achieve improvement in insight and cognition. Addressing issues of partial and non-compliance is a significant consideration in relapse prevention strategies for patients with schizophrenia, given the devastating consequences associated with psychotic relapses. © 2007 Taylor & Francis.

Language: en

Keywords

human; cognition; quality of life; Schizophrenia; Psychosis; schizophrenia; treatment outcome; clozapine; review; substance abuse; mental disease; clinical practice; prescription; priority journal; quetiapine; disease course; statistical significance; drug safety; patient compliance; drug efficacy; extrapyramidal symptom; olanzapine; risperidone; drug tolerability; tremor; weight gain; drug withdrawal; hyperprolactinemia; side effect; atypical antipsychotic agent; health care utilization; metabolic disorder; ziprasidone; schizoaffective psychosis; rigidity; Adherence; sertindole; perphenazine; motor dysfunction; aripiprazole; Antipsychotic; treatment duration; Partial compliance